January 20, 2009

Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results

2008 Full-Year Sales of $63.7 Billion increased 4.3%; Full-Year EPS was $4.57
2008 Fourth-Quarter Sales of $15.2 Billion decreased 4.9%; EPS was $0.97
Excluding Special Items, 2008 Full-Year EPS was $4.55, an increase of 9.6% and
Fourth-Quarter EPS was $0.94, an increase of 6.8%*

NEW BRUNSWICK, N.J., Jan 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced sales for the year 2008 of $63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6% and a positive currency impact of 5.1%. Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007. Operational results declined 1.0% and the negative impact of currency was 3.9%. Domestic sales decreased 6.9%, while international sales decreased 2.7%, reflecting operational growth of 5.4% and a negative currency impact of 8.1%.

Net earnings and diluted earnings per share for the year 2008 were $12.9 billion and $4.57. Full-year 2008 net earnings included special items related to in-process research and development charges of $181 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation settlements in the fourth quarter. Full-year 2007 net earnings included special items related to an in-process research and development charge of $807 million with no tax benefit, an after-tax charge of $528 million for restructuring, an after-tax non-cash charge of $441 million for the NATRECOR intangible asset write-down, and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. Excluding these special items, net earnings for 2008 were $12.9 billion and earnings per share were $4.55, representing increases of 6.8% and 9.6%, respectively, as compared with the same period in 2007. *

Net earnings and diluted earnings per share for the fourth quarter of 2008 were $2.7 billion and $0.97, respectively. Fourth quarter 2008 net earnings included special items related to in-process research and development charges of $141 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation settlements. Fourth quarter 2007 net earnings included special items related to an after-tax non-cash charge of $441 million for the NATRECOR asset write-down and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. Excluding these special items, net earnings for the current quarter were $2.6 billion and diluted earnings per share were $0.94, representing increases of 3.1% and 6.8%, respectively, as compared to the same period in 2007. *

The Company announced earnings guidance for full-year 2009 of $4.45 to $4.55 per share, which excludes the impact of special items. This guidance includes anticipated dilution of $.03 to $.05 from the acquisition of Mentor Corporation, which is expected to close in January 2009.

"I am extremely proud of Johnson & Johnson's accomplishments in 2008 and the way our people met our commitments," said William C. Weldon, Chairman and Chief Executive Officer. "We delivered solid earnings growth and made significant progress in our research pipelines while continuing to invest in the future growth of our business. I am confident that we are well positioned for continued leadership and growth in health care."

The Worldwide Consumer segment achieved annual sales in 2008 of $16.0 billion, an increase of 10.8% over the prior year with operational growth of 8.3% and a positive impact from currency of 2.5%. Domestic sales increased 8.3%, while international sales increased 12.8% (8.3% from operations and 4.5% from currency).

Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; the skin care lines of NEUTROGENA, AVEENO and CLEAN & CLEAR; international sales of Baby Care products; and LISTERINE antiseptic mouthrinse. Also contributing to growth were sales from the recently completed acquisition of DABAO, the leading moisturizer in China.

Worldwide Pharmaceutical sales of $24.6 billion for the full-year 2008 represented a decrease of 1.2% versus the prior year with a decline of 3.1% operationally and a positive impact from currency of 1.9%. Domestic sales decreased 4.9%, while international sales increased 5.1% (0.1% from operations and 5.0% from currency).

Sales results reflect the strong performance of VELCADE, a treatment for multiple myeloma; REMICADE, a biologic approved for the treatment of a number of immune mediated inflammatory diseases; RISPERDAL CONSTA, an antipsychotic medication; and TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches. Sales results of RISPERDAL, an antipsychotic medication, were negatively impacted by generic competition and sales of PROCRIT, a product for the treatment of anemia, were lower due to a decline in the market.

During the quarter, the Company announced that the U.S. Food and Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults 18 years of age or older. In addition, the Company submitted two New Drug Applications to the FDA: trabectedin (known as YONDELIS outside the U.S.) when administered in combination with DOXIL for the treatment of women with relapsed ovarian cancer and carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older. The FDA also granted PREZISTA, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults and traditional approval as twice-daily for use in treatment-experienced adult patients. Outside the United States, the European Commission granted full approval of the Marketing Authorization of PREZISTA in combination with ritonavir and other antiretroviral medicinal products for the treatment of HIV-1 infection, and extended the indication to include all treatment-experienced adult patients.

Worldwide, the Medical Devices and Diagnostics segment achieved annual sales of $23.1 billion in 2008, representing an increase over the prior year of 6.4% with operational growth of 3.5% and a positive currency impact of 2.9%. Domestic sales increased 1.0%, while international sales increased 11.3% (5.8% from operations and 5.5% from currency).

Primary contributors to the operational growth included Ethicon Endo-Surgery's minimally invasive products; Vistakon's disposable contact lenses; and DePuy's orthopaedic joint reconstruction and sports medicine businesses. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market.

During the quarter, the Company completed the acquisition of SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL family of devices, and the divestiture of Ethicon's Professional Wound Care business to One Equity Partners. In addition, the Company completed the acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.

Also in the quarter, the Company entered into a definitive agreement to acquire Mentor Corporation, a leading supplier of medical products for the global aesthetic market.

The Company also announced 510(k) clearance from the FDA for the VITROS 5600 Integrated System, a next generation system uniquely designed to integrate clinical chemistry and immunoassay testing to increase laboratory productivity, and the VITROS 3600 Immunodiagnostic System, a new high-capacity system which combines accuracy and efficiency with a broad menu of immunoassays.

As an initial step in the creation of a wellness and prevention business platform, the Company completed two acquisitions during the quarter: HealthMedia, Inc., a privately held company that creates web-based behavior change interventions, and LGE Performance Systems, Inc., a privately held company known as Human Performance Institute, which develops science-based training programs to improve employee engagement and productivity.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges and restructuring charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at www.jnj.com.

Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, sales of key products/franchises and a pharmaceutical pipeline of selected compounds in late stage development. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data


    (Unaudited; Dollars in Millions)              FOURTH QUARTER
    --------------------------------              --------------
                                                      Percent Change
                                                      --------------
                                 2008   2007     Total   Operations Currency
    ---------------------        ----   ----     -----   ---------- --------
    Sales to customers by
    segment of business

    Consumer
     U.S.                      $1,655  1,626       1.8%     1.8         -
     International              2,200  2,184       0.7     10.6      (9.9)
    ---------------             -----  -----       ---     ----      ----
                                3,855  3,810       1.2      6.9      (5.7)
                                -----  -----       ---      ---      ----

    Pharmaceutical
     U.S.                       3,430  3,944     (13.0)   (13.0)        -
     International              2,255  2,453      (8.1)     0.5      (8.6)
    --------------              -----  -----      ----      ---      ----
                                5,685  6,397     (11.1)    (7.8)     (3.3)
                                -----  -----     -----     ----      ----

    Med Devices & Diagnostics
     U.S.                       2,582  2,661      (3.0)    (3.0)        -
     International              3,060  3,089      (0.9)     5.6      (6.5)
    --------------              -----  -----      ----      ---      ----
                                5,642  5,750      (1.9)     1.6      (3.5)
                                -----  -----      ----      ---      ----

    U.S.                        7,667  8,231      (6.9)    (6.9)        -
    International               7,515  7,726      (2.7)     5.4      (8.1)
    -------------               -----  -----      ----      ---      ----
    Worldwide                 $15,182 15,957      (4.9)%   (1.0)     (3.9)
    ---------                 ------- ------      ----     ----      ----



    (Unaudited; Dollars in Millions)           TWELVE MONTHS
    --------------------------------           -------------
                                                      Percent Change
                                                      --------------
                                 2008   2007     Total  Operations  Currency
    ---------------------        ----   ----     -----  ----------  --------
    Sales to customers by
    segment of business

    Consumer
     U.S.                      $6,937  6,408       8.3%     8.3         -
     International              9,117  8,085      12.8      8.3       4.5
    ---------------             -----  -----      ----      ---       ---
                               16,054 14,493      10.8      8.3       2.5
                               ------ ------      ----      ---       ---

    Pharmaceutical
     U.S.                      14,831 15,603      (4.9)    (4.9)        -
     International              9,736  9,263       5.1      0.1       5.0
    --------------              -----  -----       ---      ---       ---
                               24,567 24,866      (1.2)    (3.1)      1.9
                               ------ ------      ----     ----       ---

    Med Devices & Diagnostics
     U.S.                      10,541 10,433       1.0      1.0         -
     International             12,585 11,303      11.3      5.8       5.5
    --------------             ------ ------      ----      ---       ---
                               23,126 21,736       6.4      3.5       2.9
                               ------ ------       ---      ---       ---

    U.S.                       32,309 32,444      (0.4)    (0.4)        -
    International              31,438 28,651       9.7      4.6       5.1
    -------------              ------ ------       ---      ---       ---
    Worldwide                 $63,747 61,095       4.3%     1.9       2.4
    ---------                 ------- ------       ---      ---       ---



    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data

    (Unaudited; Dollars in Millions)             FOURTH QUARTER
    --------------------------------             --------------
                                                        Percent Change
                                                        --------------
                              2008      2007     Total   Operations  Currency
                              ----      ----     -----   ----------  --------
    Sales to customers
    by geographic area

    U.S.                    $7,667     8,231      (6.9)%     (6.9)        -
    ----                    ------     -----      ----       ----       ---

    Europe                   3,851     4,159      (7.4)       2.7     (10.1)
    Western Hemisphere
     excluding U.S.          1,187     1,309      (9.3)       6.0     (15.3)
    Asia-Pacific,
     Africa                  2,477     2,258       9.7        9.9      (0.2)
    -------------            -----     -----       ---        ---      ----
    International            7,515     7,726      (2.7)       5.4      (8.1)
    -------------            -----     -----      ----        ---      ----

    Worldwide              $15,182    15,957      (4.9)%     (1.0)     (3.9)
    ---------              -------    ------      ----       ----      ----


                                               TWELVE MONTHS
                                               -------------
                                                         Percent Change
                                                         --------------
                              2008      2007     Total    Operations  Currency
                              ----      ----     -----    ----------  --------
    Sales to customers
    by geographic area

    U.S.                   $32,309    32,444      (0.4)%     (0.4)        -
    ----                   -------    ------      ----       ----       ---

    Europe                  16,782    15,644       7.3        1.8       5.5
    Western Hemisphere
     excluding U.S.          5,173     4,681      10.5        7.7       2.8
    Asia-Pacific,
     Africa                  9,483     8,326      13.9        8.4       5.5
    -------------            -----     -----      ----        ---       ---
    International           31,438    28,651       9.7        4.6       5.1
    -------------           ------    ------       ---        ---       ---

    Worldwide              $63,747    61,095       4.3%       1.9       2.4
    ---------              -------    ------       ---        ---       ---



    Johnson & Johnson and Subsidiaries
    -----------------------------------
    Condensed Consolidated Statement of Earnings

    (Unaudited; in Millions Except
     Per Share Figures)                    FOURTH QUARTER
    ------------------------------         --------------
                                2008                2007
                         ------------------  --------------------   Percent
                                   Percent               Percent    Increase
                         Amount    to Sales   Amount     to Sales   (Decrease)
    ------------------   ------    --------   ------     --------   ---------
    Sales to customers  $15,182       100.0  $15,957        100.0      (4.9)
    ------------------  -------       -----  -------        -----      ----
    Cost of products
     sold                 4,372        28.8    4,734         29.7      (7.6)
    Selling,
     marketing and
     administrative
     expenses             5,665        37.3    5,721         35.8      (1.0)
    Research expense      2,108        13.9    2,328         14.6      (9.5)
    In-process research
     & development
     (IPR&D)                141         0.9        -            -
    Restructuring expense     -           -        -            -
    Interest (income)
     expense, net            17         0.1      (35)        (0.2)
    Other (income)
     expense, net          (638)       (4.2)     877          5.5
    ---------------------  ----        ----      ---          ---      ----
    Earnings before
     provision for taxes
     on income            3,517        23.2    2,332         14.6      50.8
    Provision for taxes on
     income                 803         5.3      (42)        (0.3)       NM*
    ----------------------  ---         ---      ---         ----        --
    Net earnings         $2,714        17.9   $2,374         14.9      14.3
    ------------         ------        ----   ------         ----      ----

    Net earnings per
     share  (Diluted)     $0.97                $0.82                   18.3

    Average shares
     outstanding
     (Diluted)          2,801.6              2,889.2

    Effective tax rate     22.8%                (1.8)%

    ------------------
    Adjusted earnings
     before provision
     for taxes and net
     earnings
      Earnings before
       provision for
       taxes on
       income            $3,279 (1)    21.6   $3,010 (2)     18.9       8.9
      Net earnings       $2,626 (1)    17.3   $2,548 (2)     16.0       3.1
      Net earnings per
       share  (Diluted)   $0.94 (1)            $0.88 (2)                6.8
      Effective tax rate   19.9%                15.3%
    --------------------   ----                 ----

    (1) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income, net earnings and net earnings per
    share (diluted) is the exclusion of IPR&D of $141 million with no tax
    benefit and $0.05 per share, respectively and the exclusion of income
    representing the net impact of litigation settlements of $379 million,
    $229 million, and $0.08 per share, respectively.

    (2) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income, net earnings and net earnings per
    share (diluted) is the exclusion of the NATRECOR(R) intangible asset
    write-down of $678 million, $441 million, and $0.15 per share,
    respectively, and the exclusion of an international tax gain on
    restructuring of $267 million on net earnings, and $0.09 per share.

    *Not meaningful



    Johnson & Johnson and Subsidiaries
    -----------------------------------
    Condensed Consolidated Statement of Earnings


    (Unaudited; in Millions
     Except Per Share Figures)              TWELVE MONTHS
    --------------------------              -------------
                                2008                  2007
                         ------------------    ------------------   Percent
                                   Percent                Percent   Increase
                         Amount    to Sales    Amount    to Sales  (Decrease)
    ------------------   ------    --------    ------    --------   ---------
    Sales to customers  $63,747     100.0      $61,095     100.0        4.3
    ------------------  -------     -----      -------     -----        ---
    Cost of products
     sold                18,511      29.1       17,751      29.1        4.3
    Selling, marketing
     and administrative
     expenses            21,490      33.7       20,451      33.5        5.1
    Research expense      7,577      11.9        7,680      12.6       (1.3)
    In-process research
     & development
     (IPR&D)                181       0.3          807       1.3
    Restructuring expense     -         -          745       1.2
    Interest
     (income)expense, net    74       0.1         (156)     (0.3)
    Other (income)
     expense, net        (1,015)     (1.6)         534       0.9
    -------------------  ------      ----          ---       ---       ----
    Earnings before
     provision for taxes
     on income           16,929      26.5       13,283      21.7       27.4
    Provision for taxes
     on income            3,980       6.2        2,707       4.4       47.0
    --------------------  -----       ---        -----       ---       ----
    Net earnings        $12,949      20.3      $10,576      17.3       22.4
    ------------        -------      ----      -------      ----       ----

    Net earnings per
     share  (Diluted)     $4.57                  $3.63                 25.9

    Average shares
     outstanding
     (Diluted)          2,835.6                2,910.7

    Effective tax rate     23.5%                  20.4%

    -----------------------
    Adjusted earnings
     before provision for
     taxes and net earnings

      Earnings before
       provision for taxes
       on income        $16,731 (1)  26.2      $15,513 (2)  25.4        7.9
      Net earnings      $12,901 (1)  20.2      $12,085 (2)  19.8        6.8
      Net earnings per
       share  (Diluted)   $4.55 (1)              $4.15 (2)              9.6
      Effective tax rate   22.9%                  22.1%
    --------------------   ----                   ----

    (1) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income, net earnings and net earnings per
    share (diluted) is the exclusion of IPR&D of $181 million with no tax
    benefit and $0.06 per share, respectively, and the exclusion of income
    representing the net impact of litigation settlements in the fourth
    quarter of $379 million, $229 million, and $0.08 per share, respectively.

    (2) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income, net earnings and net earnings per
    share (diluted) is the exclusion of IPR&D of $807 million with no tax
    benefit and $0.28 per share, respectively, the exclusion of the
    restructuring expense of $745 million, $528 million and $0.18 per share,
    respectively, the exclusion of the NATRECOR(R) intangible asset write-down
    of $678 million, $441 million, and $0.15 per share, respectively, and the
    exclusion of an international tax gain on restructuring of $267 million on
    net earnings, and $0.09 per share.




                             REPORTED SALES vs. PRIOR PERIOD
                             -------------------------------
                                           $MM
                                           ---

                                       FOURTH QUARTER
                                       --------------
                                                   % Change
                                        -----------------------------------
                       2008   2007      Reported  Operational (1)  Currency
                       ----   ----      --------  ---------------  --------

    PHARMACEUTICAL SEGMENT  (2) (3)
    -------------------------------

    ACIPHEX/PARIET
    --------------
    US                  140    166        -15.7%       -15.7%          -
    Intl                134    181        -26.0%       -15.5%      -10.5%
    WW                  274    347        -21.0%       -15.6%       -5.4%

    CONCERTA
    --------
    US                  208    222         -6.3%        -6.3%          -
    Intl                 72     67          7.5%        34.3%      -26.8%
    WW                  280    289         -3.1%         3.1%       -6.2%

    DURAGESIC/FENTANYL TRANSDERMAL
    ------------------------------
    US                   72     72          0.0%         0.0%          -
    Intl                200    192          4.2%        10.4%       -6.2%
    WW                  272    264          3.0%         7.5%       -4.5%

    LEVAQUIN/FLOXIN
    ---------------
    US                  393    409         -3.9%        -3.9%          -
    Intl                 18     23        -21.7%        -7.7%      -14.0%
    WW                  411    432         -4.9%        -4.2%       -0.7%

    PROCRIT/EPREX
    --------------
    US                  318    331         -3.9%        -3.9%          -
    Intl                242    297        -18.5%        -8.2%      -10.3%
    WW                  560    628        -10.8%        -5.9%       -4.9%

    RAZADYNE/REMINYL
    ----------------
    US                   11     49        -77.6%       -77.6%          -
    Intl                 91     92         -1.1%        12.1%      -13.2%
    WW                  102    141        -27.7%       -19.1%       -8.6%

    REMICADE
    --------
    US                  672    661          1.7%         1.7%          -
    US Exports (4)      209    246        -15.0%       -15.0%          -
    Intl                  5      1        400.0%       385.4%       14.6%
    WW                  886    908         -2.4%        -2.4%          -

    RISPERDAL/RISPERIDONE
    ----------------------
    US                   91    570        -84.0%       -84.0%          -
    Intl                194    304        -36.2%       -33.6%       -2.6%
    WW                  285    874        -67.4%       -66.5%       -0.9%

    RISPERDAL CONSTA
    ----------------
    US                  117    108          8.3%         8.3%          -
    Intl                202    187          8.0%        20.9%      -12.9%
    WW                  319    295          8.1%        16.3%       -8.2%

    TOPAMAX
    -------
    US                  576    535          7.7%         7.7%          -
    Intl                104    117        -11.1%         0.9%      -12.0%
    WW                  680    652          4.3%         6.4%       -2.1%

    VELCADE
    -------
    US                    -      3       -100.0%      -100.0%          -
    Intl                208    162         28.4%        35.9%       -7.5%
    WW                  208    165         26.1%        33.5%       -7.4%

    OTHER
    -----
    US                  623    572          8.9%         8.9%          -
    Intl                785    830         -5.4%         3.2%       -8.6%
    WW                1,408  1,402          0.4%         5.5%       -5.1%

    TOTAL PHARMACEUTICAL
    --------------------
    US                3,430  3,944        -13.0%       -13.0%          -
    Intl              2,255  2,453         -8.1%         0.5%       -8.6%
    WW                5,685  6,397        -11.1%        -7.8%       -3.3%



                                        TWELVE MONTHS
                                                   % Change
                                        -----------------------------------
                       2008   2007      Reported  Operational (1)  Currency
                       ----   ----      --------  ---------------  --------

    PHARMACEUTICAL SEGMENT  (2) (3)
    -------------------------------

    ACIPHEX/PARIET
    --------------
    US                  539    645         -16.4%      -16.4%          -
    Intl                619    712         -13.1%      -16.6%        3.5%
    WW                1,158  1,357         -14.7%      -16.6%        1.9%

    CONCERTA
    --------
    US                  830    798           4.0%        4.0%          -
    Intl                417    230          81.3%       77.4%        3.9%
    WW                1,247  1,028          21.3%       20.4%        0.9%

    DURAGESIC/FENTANYL TRANSDERMAL
    ------------------------------
    US                  271    391         -30.7%      -30.7%          -
    Intl                765    773          -1.0%       -6.3%        5.3%
    WW                1,036  1,164         -11.0%      -14.5%        3.5%

    LEVAQUIN/FLOXIN
    ---------------
    US                1,510  1,564          -3.5%       -3.5%          -
    Intl                 81     82          -1.2%       -1.0%       -0.2%
    WW                1,591  1,646          -3.3%       -3.3%        0.0%

    PROCRIT/EXPREX
    --------------
    US                1,332  1,690         -21.2%      -21.2%          -
    Intl              1,128  1,195          -5.6%      -10.5%        4.9%
    WW                2,460  2,885         -14.7%      -16.7%        2.0%

    RAZADYNE/REMINYL
    ----------------
    US                  134    194         -30.9%      -30.9%          -
    Intl                407    337          20.8%       15.1%        5.7%
    WW                  541    531           1.9%       -1.7%        3.6%

    REMICADE
    --------
    US                2,810  2,534          10.9%       10.9%          -
    US Exports (4)      927    792          17.0%       17.0%          -
    Intl                 11      1        1000.0%      976.8%       23.2%
    WW                3,748  3,327          12.7%       12.7%          -

    RISPERDAL/RISPERIDONE
    ----------------------
    US                1,287  2,198         -41.4%      -41.4%          -
    Intl                839  1,222         -31.3%      -35.6%        4.3%
    WW                2,126  3,420         -37.8%      -39.3%        1.5%

    RISPERDAL CONSTA
    ----------------
    US                  456    422           8.1%        8.1%          -
    Intl                853    706          20.8%       15.2%        5.6%
    WW                1,309  1,128          16.0%       12.5%        3.5%

    TOPAMAX
    -------
    US                2,250  2,006          12.2%       12.2%          -
    Intl                481    447           7.6%        3.4%        4.2%
    WW                2,731  2,453          11.3%       10.5%        0.8%

    VELCADE
    -------
    US                    4      8         -50.0%      -50.0%          -
    Intl                783    526          48.9%       42.1%        6.8%
    WW                  787    534          47.4%       40.7%        6.7%

    OTHER
    -----
    US                2,481  2,361           5.1%        5.1%          -
    Intl              3,352  3,032          10.6%        4.0%        6.6%
    WW                5,833  5,393           8.2%        4.5%        3.7%

    TOTAL PHARMACEUTICAL
    --------------------
    US               14,831 15,603          -4.9%       -4.9%          -
    Intl              9,736  9,263           5.1%        0.1%        5.0%
    WW               24,567 24,866          -1.2%       -3.1%        1.9%


    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)
    (3) Prior year amounts have been reclassified to conform with current
        presentation
    (4) For external purposes, reported as U.S. sales



                                     FOURTH QUARTER
                                     --------------
                                               % Change
                                     -----------------------------------
                     2008   2007     Reported  Operational (1)  Currency
                     ----   ----     --------  ---------------  --------
    MEDICAL DEVICES AND DIAGNOSTICS  (2) (3)

    CORDIS (4)
    ----------
    US                253    394         -35.8%      -35.8%          -
    Intl              469    474          -1.1%        1.3%       -2.4%
    WW                722    868         -16.8%      -15.5%       -1.3%

    DEPUY
    -----
    US                727    661          10.0%       10.0%          -
    Intl              525    548          -4.2%        6.2%      -10.4%
    WW              1,252  1,209           3.6%        8.3%       -4.7%

    DIABETES CARE
    -------------
    US                275    337         -18.4%      -18.4%          -
    Intl              304    306          -0.7%        7.5%       -8.2%
    WW                579    643         -10.0%       -6.1%       -3.9%

    ETHICON ENDO-SURGERY
    --------------------
    US                515    481           7.1%        7.1%          -
    Intl              602    583           3.3%       11.6%       -8.3%
    WW              1,117  1,064           5.0%        9.0%       -4.0%

    ETHICON (5)
    -----------
    US                363    353           2.8%        2.8%          -
    Intl              555    591          -6.1%        3.5%       -9.6%
    WW                918    944          -2.8%        3.3%       -6.1%

    ORTHO-CLINICAL DIAGNOSTICS (5)
    ------------------------------
    US                248    245           1.2%        1.2%          -
    Intl              204    211          -3.3%        2.3%       -5.6%
    WW                452    456          -0.9%        1.7%       -2.6%

    VISION CARE
    -----------
    US                201    190           5.8%        5.8%          -
    Intl              401    376           6.6%        5.5%        1.1%
    WW                602    566           6.4%        5.7%        0.7%

    TOTAL MEDICAL DEVICES AND DIAGNOSTICS
    -------------------------------------
    US              2,582  2,661          -3.0%       -3.0%          -
    Intl            3,060  3,089          -0.9%        5.6%       -6.5%
    WW              5,642  5,750          -1.9%        1.6%       -3.5%




                                      TWELVE MONTHS
                                      -------------
                                                 % Change
                                       -----------------------------------
                     2008   2007       Reported  Operational (1)  Currency
                     ----   ----       --------  ---------------  --------
    MEDICAL DEVICES AND DIAGNOSTICS (2) (3)

    CORDIS (4)
    ----------
    US              1,235  1,588         -22.2%      -22.2%          -
    Intl            1,900  1,837           3.4%       -3.1%        6.5%
    WW              3,135  3,425          -8.5%      -12.0%        3.5%

    DEPUY
    -----
    US              2,803  2,638           6.3%        6.3%          -
    Intl            2,186  1,949          12.2%        8.3%        3.9%
    WW              4,989  4,587           8.8%        7.1%        1.7%

    DIABETES CARE
    -------------
    US              1,265  1,260           0.4%        0.4%          -
    Intl            1,270  1,113          14.1%        7.8%        6.3%
    WW              2,535  2,373           6.8%        3.9%        2.9%

    ETHICON ENDO-SURGERY
    --------------------
    US              1,901  1,792           6.1%        6.1%          -
    Intl            2,385  2,042          16.8%       11.3%        5.5%
    WW              4,286  3,834          11.8%        8.8%        3.0%

    ETHICON (5)
    -----------
    US              1,450  1,399           3.6%        3.6%          -
    Intl            2,390  2,204           8.4%        4.0%        4.4%
    WW              3,840  3,603           6.6%        3.9%        2.7%

    ORTHO-CLINICAL DIAGNOSTICS (5)
    ------------------------------
    US                997    944           5.6%        5.6%          -
    Intl              844    761          10.9%        5.0%        5.9%
    WW              1,841  1,705           8.0%        5.4%        2.6%

    VISION CARE
    -----------
    US                890    812           9.6%        9.6%          -
    Intl            1,610  1,397          15.2%        8.0%        7.2%
    WW              2,500  2,209          13.2%        8.6%        4.6%

    TOTAL MEDICAL DEVICES AND DIAGNOSTICS
    -------------------------------------
    US             10,541 10,433           1.0%        1.0%          -
    Intl           12,585 11,303          11.3%        5.8%        5.5%
    WW             23,126 21,736           6.4%        3.5%        2.9%


    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)
    (3) Prior year amounts have been reclassified to conform with current
        presentation
    (4) Includes sales of Drug-Eluting Stents for Q4 2008 of $70, $202 and
        $272 million Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for Q4 2007 of $189, $225 and
        $414 million Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for Dec YTD 2008 of $503, $852
        and $1,355 million Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for Dec YTD 2007 of $818, $943
        and $1,761 million Domestic, International and Worldwide respectively
    (5) Prior year amounts include sales previously reported as "other"




                                    FOURTH QUARTER
                                    --------------
                                               % Change
                                     -----------------------------------
                    2008   2007      Reported  Operational (1)  Currency
                    ----   ----      --------  ---------------  --------

    CONSUMER SEGMENT (2)
    ---------------------

    SKIN CARE
    ---------
    US               343    323           6.2%        6.2%         -
    Intl             501    470           6.6%       15.3%      -8.7%
    WW               844    793           6.4%       11.5%      -5.1%

    BABY CARE
    ---------
    US               109    116          -6.0%       -6.0%         -
    Intl             414    421          -1.7%        5.7%      -7.4%
    WW               523    537          -2.6%        3.2%      -5.8%

    ORAL CARE
    ---------
    US               192    189           1.6%        1.6%         -
    Intl             204    190           7.4%       19.3%     -11.9%
    WW               396    379           4.5%       10.5%      -6.0%

    OTC/NUTRITIONALS
    ----------------
    US               762    728           4.7%        4.7%         -
    Intl             694    687           1.0%       12.6%     -11.6%
    WW             1,456  1,415           2.9%        8.5%      -5.6%

    WOMEN'S HEALTH
    --------------
    US               148    148           0.0%        0.0%         -
    Intl             288    313          -8.0%        1.6%      -9.6%
    WW               436    461          -5.4%        1.1%      -6.5%

    WOUND CARE / OTHER
    ------------------
    US               101    122         -17.2%      -17.2%         -
    Intl              99    103          -3.9%        7.0%     -10.9%
    WW               200    225         -11.1%       -6.1%      -5.0%

    TOTAL CONSUMER
    --------------
    US             1,655  1,626           1.8%        1.8%         -
    Intl           2,200  2,184           0.7%       10.6%      -9.9%
    WW             3,855  3,810           1.2%        6.9%      -5.7%




                                     TWELVE MONTHS
                                     -------------
                                                % Change
                                     -----------------------------------
                    2008   2007      Reported  Operational (1)  Currency
                    ----   ----      --------  ---------------  --------

    CONSUMER SEGMENT (2)
    ---------------------

    SKIN CARE
    ---------
    US             1,462  1,329          10.0%       10.0%         -
    Intl           1,919  1,722          11.4%        6.7%       4.7%
    WW             3,381  3,051          10.8%        8.1%       2.7%

    BABY CARE
    ---------
    US               449    444           1.1%        1.1%         -
    Intl           1,765  1,538          14.8%       10.1%       4.7%
    WW             2,214  1,982          11.7%        8.0%       3.7%

    ORAL CARE
    ---------
    US               780    789          -1.1%       -1.1%         -
    Intl             844    699          20.7%       17.1%       3.6%
    WW             1,624  1,488           9.1%        7.4%       1.7%

    OTC/NUTRITIONALS
    ----------------
    US             3,061  2,620          16.8%       16.8%         -
    Intl           2,833  2,522          12.3%        8.2%       4.1%
    WW             5,894  5,142          14.6%       12.6%       2.0%

    WOMEN'S HEALTH
    --------------
    US               618    623          -0.8%       -0.8%         -
    Intl           1,293  1,183           9.3%        4.1%       5.2%
    WW             1,911  1,806           5.8%        2.4%       3.4%

    WOUND CARE / OTHER
    ------------------
    US               567    603          -6.0%       -6.0%         -
    Intl             463    421          10.0%        4.8%       5.2%
    WW             1,030  1,024           0.6%       -1.5%       2.1%

    TOTAL CONSUMER
    --------------
    US             6,937  6,408           8.3%        8.3%         -
    Intl           9,117  8,085          12.8%        8.3%       4.5%
    WW            16,054 14,493          10.8%        8.3%       2.5%


    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)


SOURCE Johnson & Johnson

 
http://www.investor.jnj.com

Copyright © 2009 PR Newswire. All rights reserved


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.